8月26日 - ** 药物开发商Allarity Therapeutics ALLR.O股价盘前上涨42%至1.34美元
** 该公司称美国FDA授予其实验性卵巢癌疗法stenoparib (link) 快速通道认证
** Stenoparib是一种口服药物，通过阻断癌细胞用于自我修复和继续生长的两种酶而起作用。
** 美国食品和药物管理局的 "快速通道 "标签旨在加快开发和审查用于治疗未满足医疗需求的严重疾病的药物
** 这种疗法最初由日本卫材公司4523.T开发，后来授权给Allarity公司，该公司获得了开发和商业化这种药物的全球权利 (link)。
** 截至上一交易日收盘，股价累计下跌20%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.